ANGPTL4通过保护KLF2抑制EndMT并减轻内皮功能障碍来预防动脉样硬化
Dong Im Cho1, Joon Ho Ahn2, Bo Gyeong Kang1
1Cell Regeneration Research Center, Chonnam National University Hospital, Gwangju, Republic of Korea. (D.I.C., B.G.K., I.H., H.H.C., J.H.J., J.Y., M.C., S.J.Y., Y.S.K., Y.A.).
Arteriosclerosis, thrombosis, and vascular biology
|August 14, 2025
概括
血管蛋白样4 (ANGPTL4) 保护对内皮炎症和内皮到介质酶过渡 (EndMT). 较低的ANGPTL4水平与冠状动脉微血管功能障碍相关,表明其作为生物标志物的潜力.
科学领域:
- 心血管生物学 心血管生物学
- 内皮细胞生物学 内皮细胞生物学
- 动脉样硬化研究 动脉样硬化研究
背景情况:
- 动脉样硬化涉及内皮功能障碍,炎症和内皮到介质细胞过渡 (EndMT).
- 血管蛋白样4 (ANGPTL4) 在内皮平衡中的作用尚不清楚.
研究的目的:
- 研究ANGPTL4对内皮炎症,血管完整性损失和EndMT的保护作用.
- 探索ANGPTL4作为冠状动脉微血管功能障碍的生物标志物的潜力.
主要方法:
- 使用了Apoe-/-小鼠,人类内皮细胞 (HUVEC,HAEC,iPSC-EC) 和人类动脉样硬化斑块.
- 在体外和体外评估EndMT标志物.
- 在冠状动脉疾病患者中分析了冠状动脉微血管功能的血ANGPTL4水平.
主要成果:
- ANGPTL4抑制了瘤亡因子-alpha和介素-1β诱导的内皮炎症,并保持了血管屏障的完整性.
- ANGPTL4通过恢复内皮标记物和抑制介质细胞标记物来抑制转化生长因子β驱动的EndMT.
- 从机制上讲,ANGPTL4减弱了TGF-β-Smad2信号传递,并恢复了克鲁佩尔样因子2 (KLF2),这对其保护作用至关重要.
- 在冠状动脉疾病和冠状动脉微血管功能障碍患者中观察到血ANGPTL4水平降低.
结论:
- ANGPTL4是内皮炎症和EndMT的关键调节者,通过TGF-β-Smad2抑制和KLF2恢复起作用.
- ANGPTL4 维护血管完整性和内皮平衡,为与EndMT相关的血管疾病提供潜在的预防剂.
- ANGPTL4可以作为冠状动脉微血管功能障碍的生物标志物.
相关概念视频
01:26Atherosclerosis III: Management
35
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
35
01:30Atherosclerosis I: Introduction
82
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
82
01:27Peripheral Artery Disease III: Interprofessional Care
29
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
29
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
225
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
01:23Atherosclerosis IV: Nursing Management
50
Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
50
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
920
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
920